Charles Keller Lab
The Keller Laboratory studies the driving mechanisms and therapeutic targets in the childhood muscle cancers, alveolar rhabdomyosarcoma and embryonal rhabdomyosarcoma, and the childhood brain tumor, medulloblastoma.
Latest from the Keller Lab Blog
Muscle Differentiation as Rhabdomyosarcoma TherapyMatthew from our lab wrote this commentary in Cancer Cell, which frames the question of how soon myo-differentiation therapy will be feasible for childhood muscle cancer. The commentary discusses the article here. Graphic illustration by Nick Escobar.
a tool for innovationWe are grateful to the Alex' Lemonade Stand Foundation for our new instrument, a Form1 3D printer. With this device we can generate custom tissue culture incubation chambers. This project is pioneered by Kirsten and Richard this Summer. stay tuned!
congratulations, Jinu![07/14/14] The article, Lineage of origin in rhabdomyosarcoma informs pharmacological response, is now available here.
[06/03/14] Congratulations to Jinu whose paper was recently accepted for publication to Genes & Development. This work was funded in part by NIH as well as the Scott Carter Foundation. Clinical translation is hopefully possible, and thus additional preclinical studies with cooperative group and pharmaceutical partners are in discussion. We are grateful to all our collaborators, especially Atiya Mansoor (OHSU), Joel Michalek and Ben Ehler and Monica Suelves (IMPPC).